GSK3B and type 2 diabetes mellitus: Following treatment, GSK-3β levels were effectively reduced in both treatments, T2DM + SITG10 (4.652 ± 0.575, p < 0.01) and T2DM + SITG30 (4.012 ± 0.269, p < 0.001), when matched to the T2DM group.